Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate

Anti-Cancer Drugs

Volumn 16, Issue 7, 2005, Pages 733-738

  Ferrari, Stefano ^a   Pieretti, Franca ^a   Verri, Elisabetta ^a   Tolentinis, Loredana ^a   Cesari, Marilena ^a   Versari, Michela ^a   Zolezzi, Carola ^a   Lamanna, Gaetano ^b   Bacci, Gaetano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cisplatin; High dose ifosfamide; High dose methotrexate; Nephrotoxicity; Osteosarcoma

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; CISPLATIN; CREATININE; DOXORUBICIN; IFOSFAMIDE; MESNA; METHOTREXATE; PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; OSTEOSARCOMA; PATIENT MONITORING; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MALE; METHOTREXATE; OSTEOSARCOMA; PROSPECTIVE STUDIES;

EID: 23344449942     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000168394.89428.11     Document Type: Article

References (18)

1. Skinner R, Sharkey IA, Pearson ADJ, Craft AW. Ifosfamide, Mesna and nephrotoxicity in children. J Clin Oncol 1993; 11:173-190.
2. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jurgens H. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994; 22:27-32.
3. Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, et al. Unilateral nephrectomt and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12:159-165.
4. Canpolat C, Pearson P, Robertson R, Jaffe N. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic and neurologic observations. Med Pediatr Oncol 1996; 26:36-47.
5. Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32:93-96.
6. Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000; 82:1636-1645.
7. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41:190-197.
8. Patel SR, Vadhan-raj S, Papadopulos N, Plager C, Burgess MA, Hays C, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose response and schedule dependence. J Clin Oncol 1997; 15:2378-2384.
9. Ferrari S, Zolezzi C, Cesari M, Fasano MC, Lamanna G, Bacci G. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide. Anticancer Drugs 1999; 10:25-31.
10. Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvolet. Pediatr Nephrol 1988; 2:183-189.
11. Holick MF, Krane SM. Introduction to bone and mineral metabolism. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (editors): Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill; 1999, pp. 2192-22196.
12. Shore R, Greenberg M, Geary D, Koren G. Ifosphamide-induced nephrotoxicity in children. Pediatr Nephrol 1992; 6:162-165.
13. Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, et al. Renal toxicity of ifosfamide in pilot regimens of intergroup rhabdomyosarcoma study for patients with gross residual disease. Am J Pediatr Hematol Oncol 1994; 16:286-295.
14. Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996; 27:149-155.
15. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999; 32:177-182.
16. Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta 2004; 346:107-118.
17. Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. Anticancer Res 2000; 20:3679-2688.
18. Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001; 3:99-102.